Solid Tumour Oncology
Innate Pharma’s clinical portfolio includes research in advanced solid tumours, with a particular focus on non-small cell lung cancer and perioperative treatment strategies in lung cancer.
- Neoadjuvant and adjuvant cancer treatment
- Pathological complete response
- Advanced cancer
The sponsor’s studies in this area reflect interest in tumour control around surgery and in treatment approaches for advanced disease.
T-Cell Lymphoma Research
The company is actively involved in clinical research for advanced T-cell lymphomas, including cutaneous T-cell lymphoma, Sezary syndrome, and mycosis fungoides.
- Relapsed and refractory disease
- Cutaneous T-cell lymphoma subtypes
- Advanced lymphoma
This area of interest centres on difficult-to-treat lymphoid malignancies with unmet therapeutic needs.
B-Cell Lymphoma and CD20-Expressing Malignancies
Innate Pharma also supports studies in relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma, extending its oncology focus to B-cell lymphoma populations.
- Non-Hodgkin lymphoma
- CD20 expression
- Relapsed/refractory lymphoma
These trials address hematologic cancer settings where treatment resistance remains a major clinical challenge.
Antineoplastic Immunotherapy
The sponsor’s research also spans investigational anticancer therapies designed to evaluate safety, tolerability, and objective response across advanced malignancies.
- Preliminary antitumour activity
- Treatment safety
- Therapeutic response
These programs support development across multiple oncology indications in Europe and other active trial regions.
